medicalxpress - For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions. In a study published today in Clinical …
AI Summary: An ultra‑sensitive circulating tumor DNA assay shows promise in tailoring treatment for older breast cancer patients by detecting molecular signals that could guide therapy decisions and avoid unnecessary interventions. The blood test aims to refine risk stratification and personalize care where standard approaches often lack nuance, potentially sparing frail patients from overtreatment.
Grail names new CEO as Bob Ragusa retires / 2 months
UCLA unveils low-cost blood test to detect multiple cancers from one sample / 7 wks
High‑dose targeted radiation shows promise for huge bile duct tumors / 1 month
Prosigna-guided OPTIMA trial shows chemo can be safely skipped in many ER+/HER2− breast cancers / 25 hrs
First‑in‑human IL‑2 cytokine factory trial shows early promise in ovarian cancer / 15 days
FDA clears blood test to guide breast cancer therapy choices / 22 days
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.